Register for our free email digests:
Division of Italfarmaco SPA
Latest From 3SBio-TNK Joint Venture
AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Italfarmaco SPA
- Senior Management
- Contact Info
Phone: (34) 91 657 23 23
Poligono Industrial de Alcobendas
San Rafael 3
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.